• Marcos Dellaretti, Matheus Tavares de Melo, Franklin Bernardes Faraj de Lima, Sofia Guazzelli, Bernardo Brant Ribeiro Costa, Pedro de Souza Silva Pereira, and Rodrigo Espindula Torres.
• Neurosurgery Department, Santa Casa BH, Belo Horizonte, Minas Gerais, Brazil; Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address: mdellaretti@mac.com.
• World Neurosurg. 2023 Jun 1; 174: 6262.

AbstractFluorescein (FS) was first used to visualize malignant brain tumors in 1948. FS accumulates in malignant gliomas where the blood-brain barrier is disrupted and provides intraoperative visualization that is similar to preoperative contrast-enhanced T1 images in which gadolinium accumulation is seen.1 FS can be viewed under white light, but the use of an operating microscope fitted with a dedicated filter (YELLOW 560 nm Filter, Carl Zeiss Meditec, Oberkochen, Germany) allows us to significantly reduce the dose needed to highlight tumoral tissue.1,2 FS is excited at 460-500 nm and emits a green, fluorescent emission wavelength at 540-690 nm.2 It is virtually free of side effects and has low costs3 (approximately 6.9 USD each vial: Brazil). Video 1 presents a case of a 63-year-old man who underwent a left temporal craniotomy to remove a temporal polar tumor. The FS is administered at the time of anesthesia before a craniotomy. The tumor was then removed with standard microneurosurgical technique by the alternating use of white light and YELLOW 560 nm filter illumination. The use of FS was found "helpful" to discriminate the brain tissue and tumor tissue (bright yellow). Fluorescein-guided technique with a dedicated filter on the surgical microscope is safe and allows complete resection of high-grade gliomas.Copyright © 2023 Elsevier Inc. All rights reserved.

25 keywords...

hide…